References
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
- Schlessinger J. Cell signaling by receptor tyrosine kinas-es. Cell 2000; 103: 211–225.
- Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183–232.
- Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implications of the ErbB/HER signal-ing network of growth factor receptors. Adv Cancer Res 2000; 77: 25–79.
- Olayioye MA, Neve RM, Lane HA, et al. The ErbB sig-naling network: Receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159–3167.
- Bucci B, D'Agnano I, Botti C, et al. EGF-R expression in ductal breast cancer: Proliferation and prognostic implica-tions. Anticancer Res 1997; 17: 769–774.
- Fox SB, Smith K, Hollyer J, et al. The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994; 29: 41–49.
- Yarden Y, Sliwkowski MX. Untangling the ErbB signal-ing network. Nat Rev Mol Cell Biol 2001; 2: 127–137.
- Fry DW, Bridges AJ, Denny WA, et al. Specific, irre-versible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A 1998; 95: 12022-12027.
- Fry DW. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des 2000; 15: 3–16.
- Hey, Zeng Q, Drenning SD, et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 pro-moter. J Natl Cancer Inst 1998; 90: 1080-1087.
- Garrison MA, Tolcher A, McCreery H, et al. A phase 1 and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors. Proc Am Soc Clin Oncol 2001; 20: 72a, (abstr 283).
- Rinehart JJ, Wilding G, Willson J, et al. A phase 1 clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002; 21: 11a (abstr 41).
- Zinner RG, Nemunaitis JJ, Donato NJ, et al. A phase I clinical and biomarker study of the novel pan-erbB tyrosine inhibitor, CI-1033 in patients with solid tumors. Clin Cancer Res 2001; 7: 3767s-3768s, (abstr 566) (suppl).